Chinese Medicine Yishen Jiangu Granules (益肾健骨颗粒) on Aromatase Inhibitor-Associated Musculoskeletal Symptoms

Xing Zhang; Nan Peng; Ming-wei Yu; Gan-lin Zhang; Xu Sun; Guo-wang Yang; Chen Li; Lin Yang; Xiao-min Wang

doi:10.1007/s11655-017-2928-4

Your Location：

Home >

Browse articles >

Chinese Medicine Yishen Jiangu Granules (益肾健骨颗粒) on Aromatase Inhibitor-Associated Musculoskeletal Symptoms

Updated：2021-08-27

- Chinese Medicine Yishen Jiangu Granules (益肾健骨颗粒) on Aromatase Inhibitor-Associated Musculoskeletal Symptoms
- Chinese Journal of Integrative Medicine Vol. 24, Issue 11, Pages: 867-872(2018)
- Affiliations：
  
  1. Department of Oncology, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University,Beijing,China
  2. Graduate School, Beijing University of Chinese Medicine,Beijing,China
- Author bio：
- Funds：
  
  Supported by Beijing Municipal Science and Technology Commission, China (N o . D 1 3 1 1 0 0 0 0 2 2 1 3 0 0 1 , D161100005116005) and Beijing Municipal Administration of Hospitals, China (No. QML20150903)
- DOI：10.1007/s11655-017-2928-4
  CLC：
- Published：2018，
  
  Published Online：31 July 2018，
Scan for full text
Zhang, X., Peng, N., Yu, Mw. et al. Chinese Medicine Yishen Jiangu Granules (益肾健骨颗粒) on Aromatase Inhibitor-Associated Musculoskeletal Symptoms., Chin. J. Integr. Med. 24, 867–872 (2018). https://doi.org/10.1007/s11655-017-2928-4

Xing Zhang, Nan Peng, Ming-wei Yu, et al. Chinese Medicine Yishen Jiangu Granules (益肾健骨颗粒) on Aromatase Inhibitor-Associated Musculoskeletal Symptoms. [J]. Chinese Journal of Integrative Medicine 24(11):867-872(2018)
Zhang, X., Peng, N., Yu, Mw. et al. Chinese Medicine Yishen Jiangu Granules (益肾健骨颗粒) on Aromatase Inhibitor-Associated Musculoskeletal Symptoms., Chin. J. Integr. Med. 24, 867–872 (2018). https://doi.org/10.1007/s11655-017-2928-4 DOI：

Xing Zhang, Nan Peng, Ming-wei Yu, et al. Chinese Medicine Yishen Jiangu Granules (益肾健骨颗粒) on Aromatase Inhibitor-Associated Musculoskeletal Symptoms. [J]. Chinese Journal of Integrative Medicine 24(11):867-872(2018) DOI： 10.1007/s11655-017-2928-4.

摘要

To assess the effectiveness of Yishen Jiangu Granules (益肾健骨颗粒

YSJGG) on aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). A single-arm

open-label study was conducted in 34 postmenopausal women with breast cancer who experienced AIMSS. Patients were treated with YSJGG for 12 weeks (12.4 g orally twice daily). The primary outcome was a change in the mean worst pain score of Brief Pain Inventory-Short Form (BPI-SF) over 12 weeks

and the second outcomes included changes in pain severity and pain-related interference of BPI-SF and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH)

the Functional Assessment of Cancer Therapy-Breast (FACT-B)

bone mineral density (BMD) and blood indices such as calcium (Ca)

phosphate (P)

and alkaline phosphatase (ALP). Of 37 women recruited

30 initiated the therapy and 24 were evaluable at 12 weeks. The primary outcome (BPI-SF worst pain scores) achieved a 2.17-point reduction compared with baseline (5.75±1.87 vs 3.58±2.15

P<0.01). There were reductions in pain severity (decreased 1.65

P<0.01) and pain-related interference (decreased 2.55

P<0.01). The changes in WOMAC and M-SACRAH scores were similar to BPI-SF (P<0.05). In the FACT-B

only physical well-being and functional well-being were improved compared with baseline (P<0.05). No clinical differences were found in BMD

P and ALP. YSJGG is an effective and well-tolerated agent to reduce AIMSS.

Abstract

To assess the effectiveness of Yishen Jiangu Granules (益肾健骨颗粒

YSJGG) on aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). A single-arm

and the second outcomes included changes in pain severity and pain-related interference of BPI-SF and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands (M-SACRAH)

the Functional Assessment of Cancer Therapy-Breast (FACT-B)

bone mineral density (BMD) and blood indices such as calcium (Ca)

phosphate (P)

and alkaline phosphatase (ALP). Of 37 women recruited

30 initiated the therapy and 24 were evaluable at 12 weeks. The primary outcome (BPI-SF worst pain scores) achieved a 2.17-point reduction compared with baseline (5.75±1.87 vs 3.58±2.15

P<0.01). There were reductions in pain severity (decreased 1.65

P<0.01) and pain-related interference (decreased 2.55

P<0.01). The changes in WOMAC and M-SACRAH scores were similar to BPI-SF (P<0.05). In the FACT-B

only physical well-being and functional well-being were improved compared with baseline (P<0.05). No clinical differences were found in BMD

P and ALP. YSJGG is an effective and well-tolerated agent to reduce AIMSS.

关键词

aromatase inhibitorsBreast Cancermusculoskeletal symptomsChinese MedicineYishen Jiangu Granules

Keywords

aromatase inhibitorsBreast Cancermusculoskeletal symptomsChinese MedicineYishen Jiangu Granules

references

Clemons M, Coleman RE, Verma S. Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev 2004;30:325–332.

Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877–3883.

Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 2011;13:205.

Lin C, Lin X, Yang J. An observation on combined use of chemotherapy and traditional Chinese medicine to relieve cancer pain. J Tradit Chin Med 1996;16:267–269.

Jiang S, Liu H, Liu Z, Liu N, Liu R, Kang Y, et al. Adjuvant effects of fermented red ginseng extract on advanced nonsmall cell lung cancer patients treated with chemotherapy. Chin J Integr Med 2017;3:331–337.

Zhou D, ed. Oncology of traditional Chinese medicine. Beijing: China Press of Traditional Chinese Medicine; 2011:16–39.

Sun G, Tong Y, Chen W, eds. Basic theory of traditional Chinese medicine. Beijng: China Press of Traditional Chinese Medicine; 2002:72–98.

Peng N, Zhang Y, Ma C, Yu M, Yang G, Fu Q. Effects of the traditional Chinese medicine Yi Shen Jian Gu Granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial. Trials 2014;15:171.

Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2014;25 Suppl 3:iii124–137.

Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129–138.

Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833–1840.

Sautner J, Andel I, Rintelen B, Leeb BF. Development of the M–SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands). Rheumatology (Oxford) 2004;43:1409–1413.

Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy–Breast Quality-of-Life Instrument. J Clin Oncol 1997;15:974–986.

Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105–121.

Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol 2013;24:1443–1449.

Zhong L, Zhang W, Hua Y, Ji P, Yao W, Li J. et al. Metabolomic evaluation for anti-inflammatory effect of volatile oils from different preparations of Angelicae Sinensis Radix. China J Chin Mater Med (Chin) 2016;41:2061–2069.

Yang Q, Yang L, Xiong A, Lu L, Wang R, Wang Z. Metabolomics study of anti-inflammatory action of Radix Paeoniae Rubra and Radix Paeoniae Alba by ultraperformance liquid chromatography–mass spectrometry. China J Chin Mater Med (Chin) 2011;36:694–697.

Huang J, Fang M, Li Y, Ma Y, Cai X. Analgesic effect of Corydalis yanhusuo in a rat model of trigeminal neuropathic pain. J Nanfang Med Univ (Chin) 2010;30:2161–2164.

Sestak I, Sapunar F, Cuzick J. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 2009;27:4961–4965.

Hershman DL, Unger JM, Crew KD, Awad D, Dakhil SR, Gralow J, et al. Randomized multicenter placebo-controlled trial of Omega–3 fatty acids for the control of aromatase inhibitor-induced musculoskeletal pain: SWOG S0927. J Clin Oncol 2015;33:1910–1917.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effects of Shugan Jianpi Formula (疏肝健脾方) on myeloid-derived suppression cells-mediated depression breast cancer mice

Sublingual Nodules: Diagnostic Markers of Metastatic Breast Cancer

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome

Related Author

No data

Related Institution

Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medicine Sciences

Department of Oncology, Southern District of Guang’anmen Hospital, China Academy of Chinese Medicine Sciences

National Clinical Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital

Department of Medical Oncology, Tianjin Medical Universty General Hospital

Zhong-Shan-Men In-patient Department, Tianjin Medical University Cancer Institute and Hospital

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰